ChinaAMC CSI All Share Health Care Devices ETF

Mindray released FY2026 Q1 earnings on April 28 During-Market (BJT), actual revenue CNY 8.352 B (forecast CNY 8.382 B), actual EPS CNY 1.9224 (forecast CNY 1.7195)

United Imaging Healthcare released FY2026 Q1 earnings on April 28 Pre-Market (BJT), actual revenue CNY 2.908 B (forecast CNY 3.045 B), actual EPS CNY 0.48 (forecast CNY 0.5586)

Furui Co., Ltd. released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 360.14 M, actual EPS CNY 0.12

Snibe released FY2026 Q1 earnings on April 27 During-Market (BJT), actual revenue CNY 1.129 B (forecast CNY 1.193 B), actual EPS CNY 0.5625 (forecast CNY 0.5609)

Snibe released FY2025 Annual Earnings on April 27 Pre-Market (BJT), actual revenue CNY 4.577 B (forecast CNY 4.701 B), actual EPS CNY 2.0621 (forecast CNY 2.1398)

Snibe released FY2025 Q4 earnings on April 27 Pre-Market (BJT), actual revenue CNY 1.149 B (forecast CNY 1.223 B), actual EPS CNY 0.5286 (forecast CNY 0.5662)

BGI Genomics released FY2025 Q4 earnings on April 24 (BJT), actual revenue CNY 1.032 B, actual EPS CNY -1.4274

BGI Genomics released FY2025 earnings on April 24 (BJT), actual revenue CNY 3.705 B (forecast CNY 3.604 B), actual EPS CNY -1.4812 (forecast CNY 0.06)

YUYUE MEDICAL released FY2025 Q4 earnings on April 24 Pre-Market (BJT), actual revenue CNY 1.41 B (forecast CNY 1.868 B), actual EPS CNY 0.0155 (forecast CNY 0.2231)

BGI Genomics released FY2026 Q1 earnings on April 24 After-Market BJT, actual revenue CNY 808.65 M, actual EPS CNY -0.0229

YUYUE MEDICAL released FY2025 earnings on April 24 Pre-Market (BJT), actual revenue CNY 7.955 B (forecast CNY 8.462 B), actual EPS CNY 1.48 (forecast CNY 1.9106)

Yuyue Medical released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 2.37 B (forecast CNY 2.704 B), actual EPS CNY 0.4291 (forecast CNY 0.4778)

INTCO released FY2026 Q1 earnings on April 23 During-Market (BJT), actual revenue CNY 2.887 B, actual EPS CNY 0.02

Lepu Medical released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 1.544 B (forecast CNY 1.673 B), actual EPS CNY -0.0108 (forecast CNY 0.0694)

APT released FY2026 Q1 earnings on April 23 During-Market (BJT), actual revenue CNY 704.08 M (forecast CNY 718.77 M), actual EPS CNY 1.63 (forecast CNY 1.567)

Lepu Medical released FY2025 earnings on April 23 After-Market (BJT), actual revenue CNY 6.483 B (forecast CNY 6.635 B), actual EPS CNY 0.5219 (forecast CNY 0.5912)

INTCO released FY2025 Annual Earnings on April 23 After-Market (BJT), actual revenue CNY 9.926 B (forecast CNY 10.06 B), actual EPS CNY 1.57 (forecast CNY 2.035)

INTCO released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 2.501 B, actual EPS CNY 0.1302

Mindray to release FY2026 Q1 earnings report on April 29 During-Market BJT, forecast revenue CNY 8.382 B, EPS CNY 1.7242

United Imaging Healthcare to Release FY2026 Q1 Earnings on April 29 Pre-Market (BJT), Forecast Revenue CNY 3.045 B, EPS CNY 0.5586

588130

159898

512290

562600

510660

A new therapeutic approach for atopic dermatitis is being developed, utilizing a dual mechanism that targets barrier repair through KLK5/7 and inflammation inhibition through IL-13. This first-in-class treatment aims to address the needs of patients with atopic dermatitis. A Phase 2 patient proof-of-concept study focusing on moderate-to-severe cases of atopic dermatitis is planned to commence soon. This study will test the effectiveness of the treatment and its potential benefits for patients.

Unusual Whales

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Guotai CSI Bio-medicine ETF

iShares US Medical Devices

ChinaAMC SSE Health Care ETF Initiating Fund

Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial

159883

Broncus Holding Corp. announced that all resolutions at its May 14, 2026 AGM were approved by shareholders. This includes the approval of the 2025 audited financial statements, reappointment of Ernst & Young as auditor, and mandates for share issuance and buybacks. Shareholders also re-elected two non-executive directors, with varying support levels. A special resolution to amend the articles of association was also passed, enhancing the board's flexibility in capital management and governance. Broncus is a Cayman Islands-based medical company listed in Hong Kong, focusing on healthcare technologies.

Tip Ranks

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

BRONCUS-B

Broncus shareholders back all AGM resolutions, update articles of association

02170

512170

Suzhou Basecare Medical Corp. Ltd. has received NMPA Class III approval for its Gems cleavage embryo culture medium, enhancing its portfolio of certified products. This medium, developed with expertise from the Sydney IVF Center, aims to improve embryo stress resistance and support in assisted reproduction. With this approval, all four core products in the Gems series are now certified, creating a comprehensive embryo culture system for fertility specialists. The company focuses on assisted reproductive technologies and has a market cap of HK$506M.

BASECARE-B

Hwabao WP CSI Medical Service ETF

Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium

The DOJ has initiated a criminal investigation into NYU Langone Health regarding its provision of gender-affirming care for transgender youth. This marks the first known instance of such a probe targeting a hospital for this type of care. NYU Langone received a grand jury subpoena seeking information about minor patients and hospital staff involved in providing this care. The investigation follows a trend of increased scrutiny on transgender rights under the Trump administration, with over 20 subpoenas issued to various hospitals nationwide, leading many to halt gender-affirming treatments for young patients.

Yahoo Finance

China Universal 800 Health Care ETF

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

iShares US Healthcare Providers

Health Care Select Sector SPDR

SPDR S&P Health

SPDR S&P Health Equip

DOJ Launches Criminal Probe Into Blue State Hospital

159859

588250

560600

Coloplast A/S reported a Q2 loss of 971 million Danish kroner, down from a profit of 912 million kroner last year, primarily due to a 3.03 billion kroner impairment loss related to Kerecis. Despite this, revenues rose 2% to 7.08 billion kroner, with organic growth of 6%. The company reaffirmed its FY26 outlook, projecting revenue growth of 3% and adjusted EBIT growth of around 5%. A half-year interim dividend of 5.00 kroner per share will be paid.

rttnews

BlackRock, Inc.

Tianhong CNI BIOMEDICINE ETF

Penghua SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

iShares US Pharma

iShares Global Healthcare

ALPS Medical Breakthrough

Ping An CSI Medicine and Medical Device Innovation ETF

VG Health

Coloplast A/S Class B

Coloplast Slips To Loss In Q2 On Hefty Charge, Revenues Rise; Confirms FY26 Outlook

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares UltraShort Nasdaq Biotech

Novo Nordisk A/S (B Shares) ADRhedged

ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition

516610

Duno Health, Inc. has launched a new daily supplement called Youth & Vitality, formulated with NAD+ precursors and essential vitamins to support cellular renewal and overall health. The supplement aims to combat aging-related issues by boosting NAD+ levels, reducing homocysteine, and promoting cardiovascular and neuroprotection benefits. It includes nicotinamide and key B vitamins, which have been clinically tested for safety and effectiveness. The product is designed for individuals approaching 50, with a promotional offer for blood testing to measure effectiveness.

prnewswire

Dacheng CSI All Share Health Care Equipment and Services ETF

10:00 ETDuno Health launches the Youth & Vitality Daily Supplement

513060

Boule Diagnostics AB's 2026 AGM approved the 2025 financial statements, decided to retain earnings without a dividend, and granted discharge from liability to the board and CEO. The existing board structure was reaffirmed, reappointing all five directors, including chairman Torben Jørgensen. Shareholders renewed key authorizations for issuing new shares and managing the company's own shares, enhancing Boule's financial flexibility for future capital raising and strategic options. Boule Diagnostics operates in decentralized hematology and diagnostic solutions globally, with a market cap of SEK125.4M.

Bosera Hang Seng Health Care ETF(QDII)

Boule Diagnostics AGM Retains Earnings, Renews Board Mandates

520690

516930

LABU

Integrated BioPharma, Inc. (OTCQX:INBP) reported a revenue decline of 27.3% for Q1 2026, totaling $10.1 million, compared to $13.9 million in Q1 2025. The company experienced an operating loss of $1.1 million in Q1 2026, contrasting with an operating income of $0.7 million in Q1 2025. For the nine-month period ending March 31, 2026, revenue was $34.1 million, down 15.2% from $40.2 million in the same period last year, with a net loss of $1.5 million. The company attributes the revenue drop to reliance on a few major customers.

StockTitan

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

E Fund CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

SPDR S&P Biotech

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

China Merchants CSI Biotechnology Theme ETF

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026 | INBP Stock News

InventHelp has announced a new line of medical wear designed to protect healthcare workers from electromagnetic radiation emitted by medical equipment. The patent-pending invention, known as MEDICAL ATTIRE, deflects electromagnetic fields, enhancing safety and providing peace of mind. The clothing is stylish, easy to wear, and is currently available for licensing or sale to manufacturers or marketers. For more information, interested parties can contact InventHelp directly.

InventHelp Inventor Develops Medical Wear to Protect Against EMFs (SBT-2240)

ChinaAMC CSI All Share Health Care Devices ETF(562600.SH)